CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $243,608 | -39.3% | 5,367 | -24.9% | 0.00% | -50.0% |
| Q2 2023 | $401,457 | +94.3% | 7,151 | +56.5% | 0.00% | +100.0% |
| Q1 2023 | $206,656 | -34.2% | 4,569 | -5.0% | 0.00% | -50.0% |
| Q3 2022 | $314,000 | -3.4% | 4,810 | -10.0% | 0.00% | -33.3% |
| Q2 2022 | $325,000 | +25.0% | 5,347 | +29.1% | 0.00% | +50.0% |
| Q1 2022 | $260,000 | -37.2% | 4,142 | -24.2% | 0.00% | -33.3% |
| Q4 2021 | $414,000 | -46.4% | 5,465 | -20.9% | 0.00% | -50.0% |
| Q3 2021 | $773,000 | -3.9% | 6,909 | +39.1% | 0.01% | -14.3% |
| Q2 2021 | $804,000 | +34.9% | 4,966 | +1.6% | 0.01% | +16.7% |
| Q1 2021 | $596,000 | -73.5% | 4,890 | -66.6% | 0.01% | -76.0% |
| Q4 2020 | $2,245,000 | +139.3% | 14,662 | +30.7% | 0.02% | +92.3% |
| Q3 2020 | $938,000 | +340.4% | 11,220 | +123.7% | 0.01% | +160.0% |
| Q1 2020 | $213,000 | – | 5,015 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |